- Home
- ULS vs ICLR Comparison
ULS vs ICLR Comparison
Compare ULS & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ULS | ICLR |
|---|---|---|
| Founded | 1894 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 14.3B |
| IPO Year | 2024 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ULS | ICLR |
|---|---|---|
| Price | $76.59 | $185.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 14 |
| Target Price | $78.75 | ★ $201.23 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 11-04-2025 | 10-22-2025 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | ★ 10.58 | N/A |
| EPS | 1.67 | ★ 7.47 |
| Revenue | $3,003,000,000.00 | ★ $8,102,602,000.00 |
| Revenue This Year | $7.18 | N/A |
| Revenue Next Year | $5.56 | $0.76 |
| P/E Ratio | $45.86 | ★ $24.87 |
| Revenue Growth | ★ 6.68 | N/A |
| 52 Week Low | $48.54 | $125.10 |
| 52 Week High | $91.95 | $228.29 |
Technical Indicators
Market Signals| Indicator | ULS | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 34.51 | 62.18 |
| Support Level | $76.05 | $174.13 |
| Resistance Level | $91.66 | $191.15 |
| Average True Range (ATR) | 2.52 | 8.46 |
| MACD | -1.72 | 2.87 |
| Stochastic Oscillator | 3.46 | 85.77 |
Price Performance
Historical ComparisonAbout ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.